Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

Can J Gastroenterol. 2013 Oct;27(10):567-71. doi: 10.1155/2013/327120.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adalimumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Canada
  • Drug Approval
  • Gastroenterology / organization & administration*
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab
  • Practice Guidelines as Topic*
  • Practice Patterns, Physicians'
  • Societies, Medical / organization & administration*
  • Therapeutic Equivalency

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Gastrointestinal Agents
  • Infliximab
  • Adalimumab